Drug firm Lupin today said it has received establishment inspection report (EIR) from the US health regulator for its Aurangabad plant in Maharashtra.
It has received notification that the inspection carried out by the United States Food and Drug Administration (USFDA) in April 2017 at its Aurangabad facility is now closed and the agency has issued an EIR, Lupin said in a statement.
"This closes all outstanding USFDA inspections at Lupin's Aurangabad facility", it added.
Lupin Ltd's stock closed 1.91 per cent down at Rs 922.80 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
